Evolus (NASDAQ:EOLS) Sets New 52-Week High – Here’s What Happened

Evolus, Inc. (NASDAQ:EOLS)’s share price hit a new 52-week high during trading on Tuesday . The stock traded as high as $8.82 and last traded at $8.78, with a volume of 1320192 shares trading hands. The stock had previously closed at $8.39.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. HC Wainwright reaffirmed a “buy” rating and set a $13.00 target price on shares of Evolus in a research note on Tuesday. Weiss Ratings raised Evolus from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 15th. BTIG Research restated a “buy” rating and set a $13.00 price target on shares of Evolus in a report on Wednesday, June 17th. Finally, Wall Street Zen upgraded Evolus from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $14.50.

Evolus Stock Down 2.2%

The business has a 50-day moving average price of $6.95 and a two-hundred day moving average price of $5.86. The company has a market capitalization of $579.92 million, a price-to-earnings ratio of -16.88 and a beta of 1.35.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Larson Financial Group LLC lifted its stake in shares of Evolus by 136.6% in the fourth quarter. Larson Financial Group LLC now owns 4,914 shares of the company’s stock valued at $33,000 after buying an additional 2,837 shares in the last quarter. Meeder Asset Management Inc. bought a new stake in shares of Evolus during the fourth quarter worth about $34,000. California State Teachers Retirement System increased its position in shares of Evolus by 79.9% during the second quarter. California State Teachers Retirement System now owns 5,455 shares of the company’s stock worth $38,000 after acquiring an additional 2,423 shares in the last quarter. Legal & General Group Plc acquired a new stake in shares of Evolus in the 2nd quarter worth about $40,000. Finally, Wexford Capital LP acquired a new stake in shares of Evolus in the 3rd quarter worth about $37,000. Institutional investors and hedge funds own 90.69% of the company’s stock.

About Evolus

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.